Welcome to our dedicated page for Quanterix news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix stock.
Quanterix Corporation (NASDAQ: QTRX) generates news that spans scientific breakthroughs, clinical research, corporate developments, and financial performance, all centered on its ultra-sensitive Simoa biomarker detection technology and spatial biology capabilities. As a life sciences company active in testing laboratories and professional scientific services, Quanterix regularly reports on studies, collaborations, and product launches that affect disease research and diagnostics.
Investors and researchers following QTRX news will see coverage of peer‑reviewed studies that rely on Simoa assays, such as large population-based analyses of Alzheimer’s Disease Neuropathological Changes using p‑Tau 217, and multiple sclerosis research that combines GFAP and NfL biomarkers for personalized monitoring. These articles illustrate how Quanterix assays and reference databases are applied in real-world clinical and epidemiological settings.
The company also issues updates on new assay launches and platform enhancements, including commercial introductions of p‑Tau 205 and p‑Tau 212 assays for Alzheimer’s research, and developments at the Quanterix Accelerator Laboratory, which supports clinical testing and global clinical trials. News items may highlight regulatory milestones, such as clinical laboratory permits and medical device registrations for specific assay kits in various markets.
From a corporate and capital markets perspective, Quanterix news includes quarterly financial results, non‑GAAP performance metrics, and commentary on integration progress following its acquisition of Akoya Biosciences. Filings and press releases discuss cost synergies, revenue composition across product and service lines, and governance changes such as cooperation agreements with shareholders and Board structure updates.
This QTRX news page brings together these updates so readers can track scientific publications, diagnostic advancements, spatial biology integration, and financial disclosures in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
The FDA's recent approval of tofersen for treating SOD1-ALS marks a significant milestone, supported by compelling blood-based neurofilament light chain (NfL) measurements. This is the first instance of a blood biomarker being utilized as a surrogate endpoint for accelerated drug approval in neurology. Tofersen, which reduces the overproduction of SOD1 protein, demonstrated trends toward clinical benefit despite not significantly slowing disease progression in Phase III trials. The approach of using NfL measurements opens new avenues for neurodegenerative disease research and treatment, potentially impacting various conditions like Alzheimer's and multiple sclerosis. Quanterix Corporation, the developer of the Simoa NfL assay, plays a crucial role in this breakthrough, advancing biomarker use in clinical management.
Quanterix Corporation (NASDAQ: QTRX), a leader in biomarker detection, has announced that CEO Masoud Toloue will present at the Barclays Global Healthcare Conference on March 15, 2023, at 4:35 p.m. EDT. The company will also conduct one-on-one meetings with institutional investors on the same day. Investors can register for a virtual presentation via the provided link. Following the conference, the presentation and webcast will be accessible on Quanterix’s website. Quanterix is recognized for its Simoa® technology, which revolutionizes biomarker detection and supports significant research across various diseases.
Quanterix Corporation (NASDAQ: QTRX) announced its financial results for Q4 and the full year ended December 31, 2022. The company reported a Q4 GAAP revenue of $25.8 million, a 14.7% decline from the previous year, while full-year revenue was $105.5 million, down from $110.6 million in 2021. The gross margin for Q4 was 48.8%, improved from 41.1% in Q3 2022. The company reported an operating loss of $22.3 million, influenced by $10 million in restructuring costs. Despite the setbacks, the CEO noted progress in their strategic business realignment and promising advancements in Alzheimer's diagnostics.